HUMIRA is approved for the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older.

Not an actual HS patient




HUMIRA is proven as the first FDA-approved biologic for moderate to severe HS2

More than 50,000 patients with HS treated since 20153


Significantly more HUMIRA-treated adult patients achieved HiSCR at Week 12 vs Control1,4*


Durable primary endpoint HiSCR at Week 121

Response rates observed up to 3 years5


80 mg every-other-week maintenance dosing is available for adults and adolescents (≥12 years, ≥132 lb), after 2 initiation doses1

*Many adults with moderate to severe HS achieved HiSCR at Week 12, defined as ≥50% reduction from baseline in abscess and inflammatory nodule count, with no increase in abscess count and draining tunnel count.4

HUMIRA is FDA-approved to provide significant results in moderate to severe HS patients at Week 12

See data in PIONEER I and II trials:

Primary endpoint

Are you prescribing HUMIRA to patients in your practice?


View HUMIRA efficacy in HS

View post hoc analysis of lesion spread in HUMIRA-treated patients


View HUMIRA efficacy in HS

Learn more about how HUMIRA works

I am not a prescriber of medicine

View and download helpful HUMIRA resources

Learn about access for your HUMIRA patients

Female HS patient standing and smiling.
Every other week 80 mg maintenance dose for appropriate patients.

Half the injections with 80 mg every-other-week (EOW) maintenance dosing

Available for appropriate patients (≥12 years, ≥132 lb) after 2 initiation doses compared to 40 mg weekly maintenance dosing.1

Video thumbnail of navigating the unknown

"Navigating the Unknown"

Hear real stories of hidradenitis suppurativa from frontline physicians and actual patients. They are stories of systemic inflammation, lesions, and scarring.


1% non-preferred

99% of National Commercial patients have coverage for HUMIRA as a preferred, first-line targeted immunomodulator (TIM) on formulary.6


National Commercial Formulary coverage under the pharmacy benefit as of August 2022

Disadvantaged means a restriction (eg, prior authorization, step edit, quantity limits, or other medical policies) to a product that is not applied consistently across the entire therapeutic class.

Formulary Definitions: Preferred means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit or are placed on a higher tier. Preferred products may also require a step edit depending on the product’s label. First-line refers to a preferred or parity formulary status.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

Male HS patient with arms crossed and smiling.
HUMIRA Complete Savings Card
HUMIRA Complete Logo

In addition to forms and resources for your practice, HUMIRA Complete provides support and tools to help patients start and stay on track with their treatment—including injection training, the HUMIRA Complete App, and more.